Policy & Regulation
RedHill Biopharma recruiting for expanded Phase 2 opaganib/darolutamide combination study in advanced prostate cancer
2 July 2025 - RedHill Biopharma Ltd (NASDAQ: RDHL), an Israeli specialty biopharmaceutical company, announced on Tuesday the initiation of patient recruitment into the Phase 2 study evaluating the eff...
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
1 July 2025 -

Sweden-based biopharmaceutical company Camurus AB (NASDAQ STO: CAMX) announced on Tuesday that it has received marketing authorisati...

Genenta Science reports long-term survival signals in glioblastoma study as genitourinary trial advances
1 July 2025 -

Clinical stage immuno-oncology company Genenta Science SPA (NASDAQ: GNTA) on Tuesday announced long-term follow-up data from its gl...

Sensorion reports positive early results from first cohort of gene therapy trial for congenital deafness
1 July 2025 - Sensorion (Euronext Growth Paris:ALSEN), a clinical-stage biotechnology company that specialises in hearing loss therapies, on Tuesday announced preliminary positive safety and efficacy ...
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
1 July 2025 - US pharmaceutical company Amgen (NASDAQ:AMGN) announced on Monday that the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its p...
TuHURA Biosciences acquires Kineta
1 July 2025 - TuHURA Biosciences Inc (NASDAQ:HURA), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, announced on Monday the successful c...